As healthcare systems worldwide grapple with rising costs, biosimilars have emerged as a cost-effective solution to address the needs of patients with cancer and autoimmune diseases. One standout player in this space is rituximab, a monoclonal antibody biosimilar used primarily to treat cancers like non-Hodgkin’s lymphoma and chronic lymphocy

Read More